  Avir Green Hills Biotechnology (GHB, Vienna,  Austria, 

)  has started the first clinical Phase 1 study for its novel influenza vaccine  FLUVACC. FLUVACC is based on the deletion of the NS1 gene. The first eight  volunteers were vaccinated in collaboration with the Medical University Vienna  at the General Hospital. The protection rate is expected to surpass the rate  achieved with currently available vaccines. FLUVACC is administered as an  intranasal spray and differs in its method of production from the currently  available flu vaccines. In contrast to conventional influenza vaccines, which  are manufactured in chicken eggs, FLUVACC is produced in cultured cells (vero  cells). The use of reverse genetics allows quick and efficient fine-tuning to  circulating virus strains.

News

Avir Green Hills Biotechnology (GHB, Vienna, Austria, www.greenhillsbiotech.com) has started the first clinical Phase 1 study for its novel influenza vaccine FLUVACC. FLUVACC is based on the deletion of the NS1 gene.